<DOC>
	<DOCNO>NCT01555944</DOCNO>
	<brief_summary>This open , multicentre , prospective observational ( non-interventional ) study , perform Belgium . Principal objective : 1 . To evaluate prevalence cardiovascular risk factor cardiac function ( routinely evaluate ) treatment anthracyclines patient metastatic breast cancer ( MBC ) age &gt; = 65 year 2 . To observe management cardiovascular risk anthracycline treatment 3 . To compare liposomal versus non-liposomal anthracycline therapy ( ratio 1:1 ) cardiac function , outcome quality life ( EORTC QLQ-C30 ) Secondary objective : 1 . To evaluate efficacy anthracyclines progression free survival tumor response routinely measure ( e.g . recist criterion , tumor marker exams ) 2 . To evaluate cardiovascular event type : ECG change , arrhythmia , decrease ejection fraction , heart failure rate accord allocate treatment . 3 . To find quality life , e.g . describe accord EORTC QLQ-C30 criterion Karnofsky index achieve various patient subgroup 4 . To correlate therapeutic choice posology anthracyclines MBC Cardiovascular risk baseline 5 . To calculate cardiovascular risk accord SCORE</brief_summary>
	<brief_title>Prospective Observational Study Patients With Metastatic Breast Cancer Treated With Anthracyclines</brief_title>
	<detailed_description>The physician request : - To include 15 consecutive patient age &gt; = 65 year treat anthracyclines first second line MBC . The physician encourage enrol 2 arm 8 patient ( one treat liposomal one non-liposomal anthracyclines ) observation comparison . Each arm close soon 150 patient include national level . - To report cardiovascular risk factor - To provide result routinely perform cardiac evaluation treatment - To monitor routinely cardiovascular parameter treatment report afterwards - To monitor efficacy tolerance treatment , normal practice prescribes , report related variable describe objective - To ensure quality life assess EORTC QLQ-C30 questionnaire - To monitor report progression free survival cardiac event - To record transmit spontaneously report adverse event . These handle accord legal requirement Follow-up cover period 15 month follow inclusion . The study 3 visit 2 contact : - One visit entry - One visit 3 cycle anthracycline contain therapy - One visit end treatment - Contact 9 month inclusion - Contact 15 month inclusion It plan include data 15 consecutive female patient per specialize center Belgium . The total number patient aim 300 .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>woman age 65 year old confirm metastatic breast cancer ( MBC ) treat anthracyclines first second line Karnofsky score baseline 50 agree able fill EORTC QLQC30 questionnaire give inform consent woman contraIndications anthracyclines woman age &lt; 65 year old metastatic breast cancer eligible anthracycline treatment first second line MBC Karnofsky less 50 disagree unable fill EORTC QLQC30 questionnaire woman refuse sign informed consent</criteria>
	<gender>Female</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>